Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8...

全面介紹

Na minha lista:
書目詳細資料
發表在:Antimicrob Agents Chemother
Main Authors: Nichols, Wright W., Stone, Gregory G., Newell, Paul, Broadhurst, Helen, Wardman, Angela, MacPherson, Merran, Yates, Katrina, Riccobene, Todd, Critchley, Ian A., Das, Shampa
格式: Artigo
語言:Inglês
出版: American Society for Microbiology 2018
主題:
Clinical Therapeutics
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201065/
https://ncbi.nlm.nih.gov/pubmed/30061279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02590-17
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍